gms | German Medical Science

48th Meeting of the Particle Therapy Co-Operative Group

Particle Therapy Co-Operative Group (PTCOG)

28.09. - 03.10.2009, Heidelberg

Article

Send article

Carbon ion radiation therapy for high-risk meningiomas

Meeting Abstract

Search Medline for

  • S. Combs - University Hospital of Heidelberg, Department of Radiation Oncology and German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, Heidelberg
  • Chr. Hartmann - Department of Neuropathology, University Hospital of Heidelberg and Clinical Cooperation Unit Neuro-Pathology, German Cancer Research Center (dkfz), Heidelberg
  • A. Nikoghosyan - University Hospital of Heidelberg, Department of Radiation Oncology and German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, Heidelberg
  • O. Jaekel - German Cancer Research Center (DKFZ), Department of Medical Physics in Radiation Oncology and Heidelberger Ionenstrahl Therapiezentrum (HIT), Heidelberg
  • Chr. P. Karger - German Cancer Research Center (DKFZ), Department of Medical Physics in Radiation Oncology, Heidelberg
  • A. von Deimling - Department of Neuropathology, University Hospital of Heidelberg and Clinical Cooperation Unit Neuro-Pathology, German Cancer Research Center (dkfz), Heidelberg
  • M. Münter - University Hospital of Heidelberg, Department of Radiation Oncology, Heidelberg
  • P.E. Huber - University Hospital of Heidelberg, Department of Radiation Oncology and German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, Heidelberg
  • J. Debus - University Hospital of Heidelberg, Department of Radiation Oncology and Heidelberger Ionenstrahl Therapiezentrum (HIT), Heidelberg
  • D. Schulz-Ertner - University Hospital of Heidelberg, Department of Radiation Oncology and Radiological Institute (MVZ), Markus Hospital, Heidelberg/Frankfurt

PTCOG 48. Meeting of the Particle Therapy Co-Operative Group. Heidelberg, 28.09.-03.10.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. Doc09ptcog045

doi: 10.3205/09ptcog045, urn:nbn:de:0183-09ptcog0450

Published: September 24, 2009

© 2009 Combs et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Background: We analyzed outcome after a carbon ion boost in combination with precision photon radiation therapy in patients with meningiomas.

Patients and methods: Ten patients with meningiomas were treated with carbon ion radiation therapy as part of a Phase I/II trial. Carbon ion radiotherapy was conducted in conjunction with fractionated stereotactic radiation therapy (FSRT) or intensity-modulated radiation therapy (IMRT). Eight patients were treated as primary radiotherapy, in 2 patients carbon ion radiation therapy was performed as re-irradiation. Carbon ion radiation therapy was applied with a median dose of 18 Gy E, and photon radiation therapy was applied with a median dose of 50.4 Gy. Two patients with a history of former irradiation received 18 Gy E of carbon ion RT and a reduced dose of photon treatment.

Results: The median follow-up time was 77 months. Five patients died during follow-up, of which 4 died of tumor progression. In the group treated in the primary situation, actuarial survival rates after radiotherapy were 75% and 63% at 5 and 7 years. After re-irradiation, both patients died at 10 and 67 months, respectively. Actuarial local control rates after primary radiation therapy were 86% and 72% at 5 and 7 years. Two patients developed tumor recurrence after re-irradiation, 6 and 67 months after treatment.

Conclusion: In conclusion, carbon ion radiation shows promising results in patients with atypical or anaplastic meningiomas. Further evaluation in a larger, prospective study in comparison to proton radiotherapy or modern photon radiotherapy is needed to corroborate these results.